B
Bicycle Therapeutics
Therapeutics based on its proprietary bicyclic peptide product platform
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- NFNovartis Venture Fund
Series A4 investors entered at this stage
- SISV Health Investors
- SOSR One
Atlas Venture- AVAstellas Venture
Series B and later11 investors entered at this stage
- FMFairmount Funds Management
- FPForbion Capital Partners
- CCCambridge Innovation Capital
- LFLongwood Fund
- UCUniversity of Cambridge
- VHVertex Ventures HC
- ELEPFL Swiss Federal Polytechnic School of Lausanne
- DCDeep Track Capital
- ECEcoR1 Capital
Perceptive Advisors
RA Capital Management
Source: Dealroom Talent Intelligence.
Alumni founders
Former Bicycle Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
KTKymera TherapeuticsEst. 2016
Bruce BoothUnited States
NONodTheraEst. 2016
Alan WattUnited Kingdom
BBBe BioEst. 2020
Lea HachigianUnited StatesGlobal footprint
team presence
across markets
Patents
75 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bicycle Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bicycle Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
